89 related articles for article (PubMed ID: 10560752)
1. Mechanisms of human immunodeficiency virus type 1 inhibition by hydroxyurea.
Lori F; Lisziewicz J
J Biol Regul Homeost Agents; 1999; 13(3):176-80. PubMed ID: 10560752
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea: mechanisms of HIV-1 inhibition.
Lori F; Lisziewicz J
Antivir Ther; 1998; 3 Suppl 4():25-33. PubMed ID: 10723506
[TBL] [Abstract][Full Text] [Related]
3. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
Lori F; Lisziewicz J
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
[TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea.
Schläpfer E; Fischer M; Ott P; Speck RF
AIDS; 2003 Jul; 17(11):1613-20. PubMed ID: 12853743
[TBL] [Abstract][Full Text] [Related]
6. Role of immune modulation in primary HIV infection.
Lori F; Lisziewicz J
J Biol Regul Homeost Agents; 2000; 14(1):45-8. PubMed ID: 10763893
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
Lori F; Lisziewicz J
Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881
[TBL] [Abstract][Full Text] [Related]
8. Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection.
Zala C; Rouleau D; Montaner JS
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S143-50. PubMed ID: 10860899
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea, a potential new anti-HIV agent.
Torres G
GMHC Treat Issues; 1995 Jan; 9(1):7-9. PubMed ID: 11367381
[TBL] [Abstract][Full Text] [Related]
10. Is Hydroxyurea for real?
Mascolini M
J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
[TBL] [Abstract][Full Text] [Related]
11. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea--ever more fascinating.
Horn T
Notes Undergr; 1998; (No 37):1-3, 9. PubMed ID: 11365816
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.
Lori F; Malykh A; Cara A; Sun D; Weinstein JN; Lisziewicz J; Gallo RC
Science; 1994 Nov; 266(5186):801-5. PubMed ID: 7973634
[TBL] [Abstract][Full Text] [Related]
14. In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I.
Moriuchi H; Moriuchi M
Virology; 2000 Dec; 278(2):514-9. PubMed ID: 11118373
[TBL] [Abstract][Full Text] [Related]
15. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.
Barbour JD; Hecht FM; Wrin T; Segal MR; Ramstead CA; Liegler TJ; Busch MP; Petropoulos CJ; Hellmann NS; Kahn JO; Grant RM
J Infect Dis; 2004 Jul; 190(2):251-6. PubMed ID: 15216458
[TBL] [Abstract][Full Text] [Related]
16. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
Aiuti F; Mezzaroma I
AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of inhibition of the human immunodeficiency virus type 1 by the oxygen radical generating agent bleomycin.
Georgiou NA; van der Bruggen T; Oudshoorn M; de Bie P; Jansen CA; Nottet HS; Marx JJ; van Asbeck BS
Antiviral Res; 2004 Aug; 63(2):97-106. PubMed ID: 15302138
[TBL] [Abstract][Full Text] [Related]
18. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
19. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
[TBL] [Abstract][Full Text] [Related]
20. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Naeger LK; Margot NA; Miller MD
Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
